Jasper Hellweg
Stock Analyst at Argus Research
(2.75)
# 1,985
Out of 4,761 analysts
88
Total ratings
50.7%
Success rate
4.47%
Average return
Main Sectors:
Stocks Rated by Jasper Hellweg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $360 → $400 | $361.10 | +10.77% | 7 | Oct 31, 2024 | |
| ILMN Illumina | Upgrades: Buy | $150 | $94.20 | +59.24% | 7 | Aug 28, 2024 | |
| SNY Sanofi | Maintains: Buy | $55 → $60 | $54.46 | +10.17% | 2 | Jul 26, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,060 → $1,170 | $700.33 | +67.06% | 9 | Jun 25, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $465 → $550 | $484.24 | +13.58% | 7 | Jun 17, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $80 → $85 | $74.22 | +14.52% | 3 | May 30, 2024 | |
| NVO Novo Nordisk | Maintains: Buy | $115 → $125 | $88.08 | +41.92% | 1 | Feb 1, 2024 | |
| MRNA Moderna | Maintains: Buy | $160 → $140 | $35.53 | +294.03% | 4 | Sep 13, 2023 | |
| BIIB Biogen | Maintains: Buy | $320 → $350 | $140.64 | +148.86% | 3 | May 11, 2023 | |
| ABBV AbbVie | Downgrades: Hold | n/a | $202.08 | - | 2 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $200 | $160.46 | +24.64% | 6 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $16.74 | - | 1 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $290 | $191.04 | +51.80% | 4 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $100 | $129.87 | -23.00% | 3 | Jun 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $270 → $295 | $249.85 | +18.07% | 4 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $7.71 | - | 3 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $135 | $172.24 | -21.62% | 5 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $33.82 | - | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $25.34 | - | 2 | Apr 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $238.03 | - | 3 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $120.67 | - | 2 | Mar 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $53.77 | - | 4 | Oct 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $155 | $316.42 | -51.01% | 3 | Nov 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $232.34 | -61.26% | 1 | Sep 19, 2018 |
United Therapeutics
Oct 31, 2024
Maintains: Buy
Price Target: $360 → $400
Current: $361.10
Upside: +10.77%
Illumina
Aug 28, 2024
Upgrades: Buy
Price Target: $150
Current: $94.20
Upside: +59.24%
Sanofi
Jul 26, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $54.46
Upside: +10.17%
Regeneron Pharmaceuticals
Jun 25, 2024
Maintains: Buy
Price Target: $1,060 → $1,170
Current: $700.33
Upside: +67.06%
Vertex Pharmaceuticals
Jun 17, 2024
Maintains: Buy
Price Target: $465 → $550
Current: $484.24
Upside: +13.58%
AstraZeneca
May 30, 2024
Maintains: Buy
Price Target: $80 → $85
Current: $74.22
Upside: +14.52%
Novo Nordisk
Feb 1, 2024
Maintains: Buy
Price Target: $115 → $125
Current: $88.08
Upside: +41.92%
Moderna
Sep 13, 2023
Maintains: Buy
Price Target: $160 → $140
Current: $35.53
Upside: +294.03%
Biogen
May 11, 2023
Maintains: Buy
Price Target: $320 → $350
Current: $140.64
Upside: +148.86%
AbbVie
Apr 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $202.08
Upside: -
Jun 17, 2022
Maintains: Buy
Price Target: $225 → $200
Current: $160.46
Upside: +24.64%
Jan 27, 2022
Downgrades: Hold
Price Target: n/a
Current: $16.74
Upside: -
Sep 10, 2021
Maintains: Buy
Price Target: $260 → $290
Current: $191.04
Upside: +51.80%
Jun 9, 2021
Upgrades: Buy
Price Target: $100
Current: $129.87
Upside: -23.00%
May 20, 2021
Maintains: Buy
Price Target: $270 → $295
Current: $249.85
Upside: +18.07%
May 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $7.71
Upside: -
Oct 21, 2020
Upgrades: Buy
Price Target: $135
Current: $172.24
Upside: -21.62%
Sep 4, 2020
Downgrades: Hold
Price Target: n/a
Current: $33.82
Upside: -
Apr 17, 2020
Downgrades: Hold
Price Target: n/a
Current: $25.34
Upside: -
Apr 6, 2020
Downgrades: Hold
Price Target: n/a
Current: $238.03
Upside: -
Mar 24, 2020
Downgrades: Hold
Price Target: n/a
Current: $120.67
Upside: -
Oct 30, 2019
Downgrades: Hold
Price Target: n/a
Current: $53.77
Upside: -
Nov 6, 2018
Maintains: Buy
Price Target: $150 → $155
Current: $316.42
Upside: -51.01%
Sep 19, 2018
Maintains: Buy
Price Target: $85 → $90
Current: $232.34
Upside: -61.26%